ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,57
-0,38%
Bitcoin
59 997,49
-0,99%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Actualités

HCM Hutchmed (china) Limited

297,50
-6,50 (-2,14%)
30 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Hutchmed (china) Limited HCM London Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-6,50 -2,14% 297,50 17:35:10
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
306,00 298,00 309,00 297,50 304,00
plus d'informations sur les cotations »
Secteur Industriel
PHARMACEUTICALS & BIOTECHNOLOGY

Actualités Recentes

Date Heure Source Titre
26/4/202417:09ALNCNewsHutchmed notes CHMP's positive opinion for fruiquintinib..
26/4/202414:30UK RNSHutchmed (China) Limited Positive CHMP Opinion for..
22/4/202410:30UK RNSHutchmed (China) Limited Vesting of Awards Under the LTIP
08/4/202410:30UK RNSHutchmed (China) Limited 2023 Annual Report and Notice of..
05/4/202410:30UK RNSHutchmed (China) Limited Data to be Presented at AACR..
02/4/202411:32ALNCNewsHutchmed endometrial cancer treatment application accepted..
02/4/202408:00UK RNSHutchmed (China) Limited HUTCHMED and Innovent Announce NDA..
28/3/202412:08ALNCNewsHutchmed lung cancer treatment accepted for review in China
28/3/202408:00UK RNSHutchmed (China) Limited Savolitinib sNDA Accepted in China
22/3/202411:09ALNCNewsHutchmed begins registration stage for sovleplenib phase 2/3..
22/3/202408:16ALNCNews*CORRECT: Hutchmed China initiates registration for phase 3..
22/3/202408:00UK RNSHutchmed (China) Limited Initiation of Registration Stage of..
14/3/202410:00UK RNSHutchmed (China) Limited LTIP and Share Option Scheme
05/3/202409:30UK RNSHutchmed (China) Limited Vesting of awards under the LTIP
28/2/202418:31ALNCNewsEARNINGS: Hutchmed revenue surges, Craven House's loss..
28/2/202413:45UK RNSHutchmed (China) Limited Publication of Form 20-F
28/2/202412:30UK RNSHutchmed (China) Limited 2023 Full Year Results and Business..
07/2/202410:50ALNCNewsHutchmed hails fruquintinib trial results for gastric cancer..
07/2/202408:00UK RNSHutchmed (China) Limited Presentation of Phase III Data on..
02/2/202410:52ALNCNewsHutchmed says Inmagene exercises option to licence drug..
02/2/202409:37UK RNSHutchmed (China) Limited Inmagene Exercises Option for Two..
01/2/202409:30UK RNSHutchmed (China) Limited HUTCHMED to Announce 2023 Final..
30/1/202410:20ALNCNewsHutchmed celebrates cancer drug approval in hometown of Hong..
30/1/202408:12UK RNSHutchmed (China) Limited HUTCHMED Receives Marketing..
11/1/202411:17ALNCNewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China..
11/1/202408:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
29/12/202309:30UKREGHutchmed (China) Limited Blocklisting Six Monthly Return
29/12/202309:30UKREGHutchmed (China) Limited Total Voting Rights
21/12/202312:36ALNCNewsIN BRIEF: Hutchmed China renews deals with "substantial"..
21/12/202311:00UKREGHutchmed (China) Limited Overseas Regulatory Announcement
13/12/202314:56ALNCNewsHutchmed completes enrolment for fruquintinib trial
13/12/202308:00RNSNONHutchmed (China) Limited Inclusion in National Reimbursement..
07/12/202311:04UKREGHutchmed (China) Limited Overseas Regulatory Announcement
01/12/202308:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30/11/202309:30UKREGHutchmed (China) Limited Total Voting Rights
09/11/202313:16ALNCNewsHutchmed hails Takeda's fruquintinib approval from US for..
09/11/202308:00UKREGHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM)..
24/10/202310:30UKREGHutchmed (China) Limited Vesting of awards under the LTIP
16/10/202310:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29/9/202311:12ALNCNewsHutchmed notes Takeda submits fruquintinib drug application..
29/9/202310:30UKREGHutchmed (China) Limited Total Voting Rights
29/9/202310:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
14/9/202310:30UKREGHutchmed (China) Limited Director's Share Dealing
12/9/202311:26ALNCNewsIN BRIEF: Hutchmed China finalises patient enrolment for..
12/9/202310:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12/9/202308:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
31/8/202310:30UKREGHutchmed (China) Limited Total Voting Rights
29/8/202310:30ALNCNewsIN BRIEF: China grants Hutchmed's savolitinib breakthrough..
29/8/202308:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
21/8/202309:46ALNCNewsHutchmed China hails trial on sovleplenib meeting primary..

Dernières Valeurs Consultées

LSE
HCM
Hutchmed (china)
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés